MECHANISMS OF ACROLEIN ON PROLIFERATION AND APOPTOSIS

丙烯醛是一种高度亲电的α，β-不饱和醛，人类在各种环境条件下都会暴露于其中。在低剂量下，丙烯醛抑制细胞增殖而不引起细胞死亡，并且可以增强二级毒素引起的细胞凋亡。本项目的总体目标是确定丙烯醛增强细胞凋亡和抑制增殖的分子机制。要研究的假设是，丙烯醛增强细胞凋亡的二级应激源，包括细胞周期非特异性抗癌药物，这是由于基因或转录因子的变化，调节这一过程。由于丙烯醛是环磷酰胺的代谢产物，因此该假设得出结论，该抗癌药物的独特有效性是丙烯醛和磷酰胺芥子代谢产物的特征。一个相关的假设是丙烯醛介导的细胞增殖的降低是由一种或多种生长或应激相关基因或转录因子的表达的影响变化引起的，这些变化继发于丙烯醛处理后迅速耗尽的GSH的减少。本项目的具体目标是解决这些假设：1）详细评估丙烯醛增强细胞对凋亡的易感性形成二次促凋亡处理的能力;和2）确定丙烯醛处理后凋亡增强和增殖降低的机制。由于丙烯醛会短暂消耗GSH，因此将进行实验以区分与抗氧化能力丧失直接相关的效应与与转录因子或基因表达变化相关的效应（即使是继发于GSH丧失的效应，这可能使次要药物更好地接近分子靶点）。初步数据表明NF-κ B是丙烯醛的靶点。这将通过确定马来酸二乙酯（DEM）（其在不消耗GSH的剂量下阻断NF-κ B活化）影响细胞凋亡的能力和通过检查丙烯醛在不消耗GSH的剂量下对NF-κ B活化影响细胞凋亡的作用以及通过检查丙烯醛对NF-κ B和第二细胞系中细胞凋亡的作用来进一步研究。将确定其他选定的基因在丙烯醛的影响中的作用。具体地，在丙烯醛损伤后的不同时间测量AP-1的活化以及p53、c-jun、c-fos、c-myc、bcl-2、bcl-x和bax的mRNA水平和蛋白产物的任何变化。这些研究的结果将提供有关调节细胞增殖和凋亡的途径的重要新信息，并提供与低水平暴露于丙烯醛等活性物质相关的风险数据。

Acrolein is a highly electrophilic alpha, beta-unsaturated aldehyde to which humans are exposed in a variety of environmental situations. At low doses, acrolein inhibits cell proliferation without causing cell death and can enhance apoptosis from secondary toxins. The overall goals of this project are to determine the molecular mechanism(s) by which acrolein enhances apoptosis and inhibits proliferation. The hypothesis to be studied is that acrolein enhances apoptosis from secondary stressors including cell-cycle-non-specific anti-cancer drugs and that this is due to changes in genes or transcription factors regulating this process. Since acrolein is a metabolite of cyclophosphamide, this hypothesis leads to the conclusion that the unique effectiveness of this anti-cancer drug is a feature of both acrolein and the phosphoramide mustard metabolite. A related hypothesis is that the acrolein-mediated decrease in cell proliferation is caused by effecting changes in the expression of one or more growth- or stress-related genes or transcription factors secondary to a reduction in GSH which is rapidly depleted following acrolein treatment. The specific aims of this project to address these hypotheses are: 1) to assess in detail the ability of acrolein to enhance the susceptibility of cells to apoptosis form a secondary pro-apoptotic treatment; and 2) to determine the mechanism of the enhanced apoptosis and decreased proliferation following acrolein treatment. Since acrolein transiently depletes GSH, experiments will be run to differentiate effects directly related to a loss of antioxidant capacity to those related to changes in transcription factors or gene expression (even in those are secondary to the loss of GSH which may allow secondary agents better access to molecular targets). Preliminary data have implicated NF-kappaB as a target for acrolein. This will be further studied by determining the ability of diethyl maleate (DEM) (which blocks NF-kappaB activation at doses that do not deplete GSH) to affect apoptosis and by examining the effects of acrolein on NF-kappaB activation at doses that do not deplete GSH) to affect apoptosis and by examining the effects of acrolein on NF-kappaB and apoptosis in a second cell line. A role for other selected genes in the effects of acrolein will be determined. Specifically, the activation of AP-1 will be measured as well as any changes in mRNA levels and protein products of p53, c-jun, c-fos, c-myc, bcl-2, bcl-x, and bax at various times following acrolein insult. The results of these studies will provide important new information on pathways regulating cell proliferation and apoptosis, as well as provide data on the risk associated with low-level exposure to reactive species such as acrolein.